SCHEMBL678926

SCHEMBL678926

COc1ccc(-c2ccc3[nH]c4ncc(CCc5cccc(F)c5)cc4c3c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 5/20 0.44
GRIN2B Q13224 5/20 0.44
CLK4 Q9HAZ1 1/20 0.43
TP53 P04637 1/20 0.43
ALK Q9UM73 1/20 0.42
CHEK1 O14757 2/20 0.41
AURKA O14965 2/20 0.41
AURKB Q96GD4 2/20 0.41
CLK1 P49759 2/20 0.40
DYRK1A Q13627 2/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KIT P10721 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL675515 0.82 ALK (0.53) GRIN1GRIN2BALKCHEK1KDM4E
SCHEMBL675514 0.82 ALK (0.53) GRIN1GRIN2BALKCHEK1KDM4E
SCHEMBL676023 0.81 CASP3 (0.52) ALKCHEK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL675724 0.79 ALK (0.41) ALKCHEK1KDM4EKITKMT2A
SCHEMBL675220 0.78 ALK (0.48) ALKCHEK1AURKAAURKBDYRK1A
SCHEMBL676357 0.76 KIT (0.65) TP53ALKHPGDKITMEN1
SCHEMBL678626 0.74 PLAU (0.47) ALKLMNAMAPK1SMN1; SMN2KIT
SCHEMBL676049 0.74 MMP2 (0.53) ALKDYRK1AKDM4EALDH1A1HPGD
SCHEMBL678727 0.73 ALK (0.67) ALKCHEK1
SCHEMBL676194 0.73 ALK (0.67) ALKCHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 GRIN1 3167/4885GRIN2B 3712/4885CLK4 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.